Regulation of HLA-DR and costimulatory B7 molecules in human thyroid carcinoma cells: Differential binding of transcription factors to the HLA- DRα promoter

Thyroid

Volumn 8, Issue 5, 1998, Pages 361-369

  Lahat, Nitza ^a   Rahat, Michal A ^a   Sadeh, Orit ^a   Kinarty, Amalia ^a   Kraiem, Zaki ^a  

^a CARMEL MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; HLA ANTIGEN CLASS 2; HLA DR ANTIGEN; TRANSCRIPTION FACTOR;

ANTIGEN EXPRESSION; ARTICLE; CANCER GENETICS; CANCER IMMUNOLOGY; CONTROLLED STUDY; ELECTROPHORETIC MOBILITY; FLOW CYTOMETRY; GENE EXPRESSION; HLA SYSTEM; HUMAN; HUMAN CELL; IMMUNOGENETICS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA INTERACTION; PROTEIN PROTEIN INTERACTION; RAJI CELL; THYROID CARCINOMA;

EID: 0031775955     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.1998.8.361     Document Type: Article

References (49)

1. Germain RN 1986 The ins and cuts of antigen processing and presentation. Nature 322:687-689.
2. Marrack P, Kaffler J 1988 The T cell repertoire for antigen and MHC. Immunol Today 9:308-315.
3. Hanafusa T, Pujol-Borrell R, Chiovatto L, Russel RCG, Doniach D, Bottazzo GF 1983 Aberrant expression of HLA-DR antigen on thyrocytes in Graves' disease. Relevance for autoimmunity. Lancet 2:111-115.
4. Natali P, Bigotti A, Gavalieri R, Nicota MR, Tecce R, Mangredi D, Chen Y, Nadler LM, Ferrone S 1986 Gene products of the HLA-D region in malignant and normal tissue of nonlymphoid origin. Hum Immunol 15:220-233.
5. Bottazzo GF, Pujol-Borrell R, Hanafusa T 1983 Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity. Lancet 2:1115-1118.
6. Lombardi G, Arnold K, Uren J, Marelli-Berg F, Hargreaves R, Imami N, Weetman A, Lecher R 1997 Antigen presentation by IFN-γ treated thyroid follicular cells inhibits IL-2 and supports IL-4 production by B7-dependent human T cells. Eur J Immunol 27:62-71.
7. Matsuoka N, Eguchi K, Kawakami A, Tsuboi M, Nakamura H, Kimura H, Ishikawa N, Ito K, Nagataki S 1996 Lack of B7-1/BB1 and B7-2/B70 expression on thyrocytes of patients with Graves' disease. Delivery of costimulatory signals from bystander professional antigen presenting cells. J Clin Endocrinol Metab 81:4137-4143.
8. Fisfalen ME, Franklin WA, Degroot LJ, Cajulis RS, Soltani K, Ryan M, Jones N 1990 Expression of HLA-ABC and DR antigen in thyroid neoplasia and correlation with mononuclear leukocyte infiltration. J Endocrinol Invest 13:41-48.
9. Goldmith NK, Dikman S, Berma SB, Tavies TF, Roman SH 1988 HLA class II antigen expression and the autoimmune thyroid response in patients with benign and malignant thyroid tumor. Clin Immunol Immunopathol 48:161-173.
10. Ostrand-Rosenberg S, Roby C, Clements V 1990 Rejection of mouse sarcoma cells after transfection of MHC class II genes. J Immunol 144:4068-4070.
11. Ostrand-Rosenberg S, Roby C, Clements V 1991 Abrogation of tumorigenicity by MHC class II antigen expression require the cytoplasmic domain of class II molecule. J Immunol 147:2419-2423.
12. Brunner CA, Gobel JM, Riethmiller G, Johnson JP 1991 Expression of HLA-D subloci DR and DQ by breast carcinoma is correlated with distinct parameters of favorable prognosis. Eur J Cancer 27:411-416.
13. Gutiesrez J, Lopez-Nevot MA, Cabsera T, Oliva R, Esquivas J 1987 Class I and II HLA antigen distribution in normal mucosa, adenoma and colon carcinoma: Relation with malignancy and invasiveness. Exp Clin Immunogenet 4:144-152.
14. Rubin JT, Elwood LJ, Rosenberg SA, Lotze MT 1989 Immunohistochemical correlates of IL-2 based response to recombinant immunotherapy in human. Cancer Res 49:7086-7092.
15. Ransom JH, Pelle B, Hanna MG Jr. 1992 Expression of class II major histocompatibility complex molecules correlates with human colon tumor vaccine efficancy. Cancer Res 52:3460-3466.
16. Mattijssen V, DeMudder L, Schalkwif K, Manni J, Hof Grootenboer B, Ruites D 1991 HLA antigen expression in routinely processed head and neck squamous cell carcinoma primary lesions of different sites. Int J Cancer 6:(suppl) 15.
17. Moller P, Koretz K, Schlagand P, Momburg F 1991 Frequency of abnormal expression of HLA-ABC and HLA-DR molecules invariant chain and LFA-3 in colorectal carcinoma and its impact on tumor recurrence. Int J Cancer 6(suppl):155.
18. Okeane J, Mack C, Lynch E, Harrington D, Neiman R 1990 Prognostic correlation of HLA-DR expression in large cell lymphoma as determined by LN3 antibody staining. Cancer 66:1147.
19. Kingston AE, Bergsteinsdottir K, Jessen KR, Van Der Meide PH, Colston MJ, Mirski R 1989 Schwann cells co-cultured with stimulated T cells and antigen express MHC II determinants without interferon-γ pretreatment: Synergistic effects of interferon-γ and tumor necrosis factor on MHC class II induction. Eur J Immunol 19:177-183.
20. Buscema M Todd, Deuss IU, Hammond L, Pujol Borrell R, Bottazzo GF 1989 Influence of TNF on the modulation of γIFN on HLA class II in human thyroid cells and its effects in γIFN binding. J Clin Endocrinol Metabol 69:433-439.
21. Lahat N, Hiros W, Davies TF 1989 Enhanced induction of thyroid cell MHC class II antigen expression in rats highly responsive to thyroglobulin. Endocrinology 24:1754-1759.
22. Lahat N, Sheinfeld M, Sobel E, Kinarty A, Kraiem Z 1992 Divergent effects of cytokines on human leukocyte antigen-DR antigen expression of neoplastic and nonneoplastic human thyroid cells. Cancer 69:1799-1807.
23. Lahat N, Sheinfeld M, Sobel E, Baron E, Kraiem Z 1990 Class II HLA-DR antigens on non-autoimmune human thyroid cells stimulate autologous T cells with high suppressor activity. Autoimmunity 4:125-133.
24. Lahat N, Sobel E, Kraiem Z 1993 Control of HLA-DR antigen expression by γ-interferon: separate signal transduction mechanisms in malignant and nonmalignant human thyroid cells. Cancer Res 53:3943-3947.
25. Neufeld DS, Lahat N, Graves P, Gillon-Peled M, Kraiem Z, Davies TF 1993 HLA-DRα gene regulation in immortalized human thyroid cancer cells. Clin Immunol Immunopathol 67:151-156.
26. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, Koeffler HP 1993 High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91:179-184.
27. Kimura H, Yamashita S, Namba H, Usa T, Fujiyama K, Tsuruta M, Yokoyama N, Izumi M, Nagataki S 1992 Impairment of the TSH signal transduction system in human thyroid carcinoma cells. Exp Cell Res 203:402-406.
28. Pang XP, Hershman JM, Chung M, Pekary AE 1989 Characterization of tumor necrosis factor α receptors in human and rat thyroid cells and regulation of the receptors by thyrotropin. Endocrinology 125:1783-1788.
29. Van Herle AJ, Agatep ML, Padua III DN, Totanes TL, Canlapan DV, Van Herle NML, Juillard GJF 1990 Effects of 13-cis-retinoic acid on growth and differentiation of human follicular carcinoma cells in vitro. J Clin Endocrinol Metabol 71:755-763.
30. Cogswell JP, Zeleznik-Le N, Ting JPY 1991 Transcriptional regulation of the HLA-DRA gene. Crit Rev Immunol 11:87-112.
31. Glimcher LH, Kara CJ 1992 Sequences and factors: A guide to MHC class II transcription. Annu Rev Immunol 10:13-49.
32. Ting JPY, Baldwin AS 1993 Regulation of MHC gene expression. Curr Opin Immunol 5:8-16.
33. Tsang SY, Nakanihi M, Peterlin BM 1990 Mutational analysis of the DRA promoter: cis-acting sequences and trans-act-ing factors. Mol Cell Biol 10:711-719.
34. Dignam JD, Russell ML, Reeder RG 1983 Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 11:1475-1489.
35. Reith W, Siegrist CA, Durand B, Barras E, Mach B 1994 Function of major histocompatability complex class II promoters requires cooperative binding between factors RFX and NF-Y. Proc Natl Acad Sci USA 91:554-558.
36. Reith W, Kobr M, Emery P, Durand B, Siegris CA, Mach B 1994 Cooperative binding between factors RFX and X2bp to the X and X2 boxes of MHC class II promoters. J Biol Chem 269:20020-20025.
37. Wright KL, Vilen BJ, Itoh-Lindstrom Y, Moore TL, Li GM, Criscitiello M, Cogswell P, Clarke JB, Ting JPY 1994 CCAAT box binding protein NF-Y facilitates in vivo recruitment of upstream dna binding transcription factors. EMBO J 13:4042-4053.
38. Kara CJ, Glimcher LH 1991 In vivo footprinting of MHC class II genes: Bare promoters in the bare lymphocyte syndrome. Science 252:709-712.
39. Liou HC, Boothby MR, Finn PW, Davidon R, Nabavi N, Zeleznik-Lee NJ, Ting JPY, Glimcher LH 1990 A new member of the leucine zipper class of proteins that binds to the HLA-DRa promoter. Science 247:1581-1584.
40. Montani V, Shong M, Taniguchi SI, Suzuki K, Giuliani C, Napolitano G, Saito J, Saji M, Fiorentino B, Reimold AM, Singer DS, Kohn LD 1998 Regulation of major histocompatibility class II gene expression in FRTL-5 thyrocytes: Opposite effects of interferon and methimazole. Endocrinology 139:290-302.
41. Reed GE, Kirchner JE, Carr LG 1995 NF-Y Activates mouse tryptophan hydroxylase transcription. Brain Res 682:1-12.
42. Siegrist CA, Durand B, Emery P, David E, Hearing P, Mach B, Reith W 1993 RFX1 is identical to enhancer factor C and functions as a transactivator of the hepatitis B virus enhancer. Mol Cell Biol 13:6375-6384.
43. Reinhold W, Emens L, Itkes A, Blake M, Ichinosew I, Zajac-Kaye M 1995 The Myc intron-binding polypeptide associates with RFX1 in vivo and binds to the major histocompatibility complex class II promoter region, to the hepatitis B virus enhancer, and to the regulatory regions of several distinct viral genes. Mol Cell Biol 15:3041-3048.
44. Safrany G, Perry R 1993 Transcription factor RFX1 helps control the promoter of the mouse ribosomal protein-encoding gene rpLSO by binding to its α element. Gene 132:279-283.
45. Steimle V, Otten LA, Zufferey M, Mach B 1993 Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell 75:135-146.
46. Steimle V, Siegrist CA, Mottet A, Lisowska-Grospierre B, Mach B 1994 Regulation of MHC class II expression by interferon-γ mediated by the transactivator gene CIITA. Science 265:106-109.
47. Zhou H, Glimcher LH 1995 Human MHC class II gene transcription directed by the carboxyl terminus of CIITA, one of the defective genes in type II MHC combined immune deficiency. Immunity 2:545-553.
48. Riley JL, Westerheide SD, Price JA, Brown JA, Boss JM 1995 Activation of class II MHC genes require both the X box region and the class II transactivator (CIITA). Immunity 2:533-543.
49. Montani V, Taniguchi SI, Shong M, Suzuki K, Ohmori M, Giuliani C, Napolitano G, Saji M, Fiorentino B, Reimold AM, Ting JP-Y, Kohn LD, and Singer DS. 1998 Major histocompatibility class II HLA-DRα gene expression in thyrocytes: Counterregulation by class II transactivator and the thyroid Y box protein. Endocrinology 139:280-289.